

**Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028**

Market Report | 2023-07-03 | 310 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The molecular diagnostics market is valued at an estimated USD 16.6 billion in 2023 and is projected to reach USD 28.6 billion by 2028 at a CAGR of 11.4% during the forecast period. Diseases such as tuberculosis, HIV/AIDS, hepatitis, sexually transmitted infections, and respiratory infections require an accurate and timely diagnosis for effective treatment and control. Molecular diagnostics play a crucial role in the detection and monitoring of these infectious diseases, driving the growth of the market in this area.

Apart from infectious disease diagnostics, molecular diagnostic techniques are increasingly being used to enhance patient management, particularly in the field of cancer. The growing prevalence of cancer globally will increase the number of specimens tested, thus creating a demand for new diagnostic procedures, including molecular diagnostics.

"Blood, serum, and plasma segment accounted for the highest growth rate in the molecular diagnostics market, by sample type, during the forecast period"

The molecular diagnostics market is bifurcated into blood, serum, and plasma, urine, and other sample types on the basis of sample type. The blood, serum, and plasma segment in molecular diagnostics is experiencing substantial growth, largely driven by the increased demand for infectious disease testing. Infectious diseases pose significant global health challenges, and the accurate and timely diagnosis of these conditions is crucial for effective disease management and public health measures.

Plasma and serum samples provide several advantages for infectious disease testing. Plasma and serum samples have wide-ranging diagnostic applications in infectious diseases, including viral, bacterial, fungal, and parasitic infections. They aid in early diagnosis, appropriate treatment selection, and the assessment of treatment response. Moreover, Blood-based molecular diagnostics have demonstrated clinical utility across a broad range of applications, including genetic testing, infectious disease diagnosis, cancer diagnostics, and monitoring disease progression.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

"Oncology testing segment accounted for the highest growth rate in the molecular diagnostics market, by application, during the forecast period"

The global molecular diagnostics market is bifurcated into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Oncology testing segment is currently witnessing the highest growth rate within the molecular diagnostics market, reflecting the increasing importance of precision medicine and personalized approaches in cancer care. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. Molecular diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage.

Through various strategic developments, pharmaceutical companies and molecular diagnostic manufacturers have increasingly focused on integrating their synergies to develop personalized medicine and companion diagnostic assays that can support the monitoring of a patient's response to a given drug therapy. This is a major factor boosting the growth of the oncology testing segment. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.

"Asia Pacific: The fastest-growing region molecular diagnostics market"

The global molecular diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in this region have witnessed growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies in the Asia Pacific countries. These factors are expected to provide significant growth opportunities for molecular diagnostic companies operating in this region.

The Asia Pacific, which has become a medical tourism hub, is considered one of the fastest-growing markets for medical procedures and devices. Low infrastructure and treatment costs and the availability of highly educated physicians have driven medical tourists to these countries, which is a major factor driving the growth of the molecular diagnostics market in this region.

The break-up of the profile of primary participants in the molecular diagnostics market:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), bioMerieux (France), QIAGEN (Netherlands), PerkinElmer Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Illumina, Inc. (US), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), Agilent Technologies, Inc. (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), MDx Health (Belgium), Biocartis (Belgium), TBG Diagnostics Limited (Australia), HTG Molecular Diagnostics, Inc. (US), Vela Diagnostics (Singapore), Amoy Diagnostics Co., Ltd. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Savyon Diagnostics (Israel), Abacus Diagnostica Oy (Finland), and geneOmbio Technologies Pvt. Ltd. (India).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services & software), test type (lab tests and PoC tests), sample type (blood, serum, and plasma, urine, and other sample types), application (infectious disease diagnostics (hepatitis, HIV, CT/NG, HAI, HPV, tuberculosis, influenza, and other infectious diseases), oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancer testing), genetic testing, and other applications, technology (polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, in situ hybridization, DNA microarrays, and other technologies), end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

product & service launches, and recent developments associated with the molecular diagnostics market. Competitive analysis of upcoming startups in the molecular diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

- Analysis of key drivers (increasing prevalence of infectious diseases and cancer globally, rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies, growing awareness of early disease diagnosis in developing countries, rising technological advancements in molecular diagnostics in recent years, and increasing use of PoC diagnostic tests in homecare settings and hospitals), restraints (unfavorable reimbursement scenario for diagnostic companies and high cost of molecular diagnostic instruments), opportunities (growing significance of companion diagnostics in drug development process and growth opportunities for molecular diagnostic companies in emerging economies), and challenges (changing regulatory landscape for IVD and molecular diagnostics in US and European Union, operational barriers and shortage of skills across major markets, and introduction of alternative technologies for disease detection and diagnosis) influencing the growth of the molecular diagnostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the molecular diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the molecular diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), and bioMérieux (France), among others in the molecular diagnostics market strategies.

## Table of Contents:

|   |    |
|---|----|
| 1□INTRODUCTION□   | 36 |
| 1.1□STUDY OBJECTIVES□   | 36 |
| 1.2□MARKET DEFINITION□  | 36 |
| 1.2.1□INCLUSIONS AND EXCLUSIONS□                                    | 37 |
| 1.3□STUDY SCOPE□  | 38 |
| 1.3.1□MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION□            | 38 |
| 1.3.2□MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL SEGMENTATION□      | 39 |
| 1.3.3□YEARS CONSIDERED□   | 39 |
| 1.4□CURRENCY CONSIDERED□  | 40 |
| 1.5□MARKET LIMITATIONS□   | 40 |
| 1.6□STAKEHOLDERS□   | 41 |
| 1.7□SUMMARY OF CHANGES□   | 41 |
| 2□RESEARCH METHODOLOGY□   | 42 |
| 2.1□RESEARCH DATA□  | 42 |
| 2.2□RESEARCH APPROACH□  | 42 |
| FIGURE 1□MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY□ | 42 |
| 2.2.1□SECONDARY DATA□   | 43 |
| 2.2.1.1□Key data from secondary sources□                            | 43 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|           |   |    |
|-----------|---|----|
| 2.2.2     | PRIMARY DATA  | 44 |
| 2.2.2.1   | Primary sources   | 45 |
| 2.2.2.2   | Key data from primary sources   | 45 |
| 2.2.2.3   | Key industry insights   | 46 |
| 2.2.2.4   | Breakdown of primary interviews   | 47 |
| FIGURE 2  | BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS                     | 47 |
| FIGURE 3  | BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION                     | 47 |
| 2.3       | MARKET SIZE ESTIMATION  | 48 |
| 2.3.1     | BOTTOM-UP APPROACH  | 48 |
| 2.3.1.1   | Approach 1: Company revenue estimation approach   | 49 |
| FIGURE 4  | BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH                                       | 49 |
| 2.3.1.2   | Approach 2: Company presentations and primary interviews                                      | 49 |
| 2.3.1.3   | Growth forecast   | 49 |
| 2.3.1.4   | CAGR projections  | 50 |
| FIGURE 5  | CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS  | 50 |
| 2.3.2     | TOP-DOWN APPROACH   | 50 |
| FIGURE 6  | MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH   | 51 |
| 2.4       | MARKET BREAKDOWN AND DATA TRIANGULATION   | 52 |
| FIGURE 7  | DATA TRIANGULATION METHODOLOGY  | 52 |
| 2.5       | MARKET SHARE ANALYSIS   | 52 |
| 2.6       | STUDY ASSUMPTIONS   | 53 |
| 2.7       | RESEARCH LIMITATIONS  | 53 |
| 2.8       | GROWTH RATE ASSUMPTIONS   | 54 |
| 2.9       | RISK ASSESSMENT   | 54 |
| 2.9.1     | RISK ASSESSMENT OF MOLECULAR DIAGNOSTICS MARKET   | 54 |
| 2.10      | IMPACT OF ECONOMIC RECESSION ON MOLECULAR DIAGNOSTICS MARKET                                  | 54 |
| 3         | EXECUTIVE SUMMARY   | 57 |
| FIGURE 8  | MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)               | 57 |
| FIGURE 9  | MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)                       | 58 |
| FIGURE 10 | MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)                     | 58 |
| FIGURE 11 | MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)                      | 59 |
| FIGURE 12 | MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)                     | 60 |
| FIGURE 13 | MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)                        | 60 |
| FIGURE 14 | MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)                          | 61 |
| 4         | PREMIUM INSIGHTS  | 63 |
| 4.1       | MOLECULAR DIAGNOSTICS MARKET OVERVIEW   | 63 |
| FIGURE 15 | INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET | 63 |
| 4.2       | MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028                             | 64 |
| FIGURE 16 | REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028                              | 64 |
| 4.3       | MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028                                     | 64 |
| FIGURE 17 | LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028   | 64 |
| 4.4       | MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028                                   | 65 |
| FIGURE 18 | BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD                       | 65 |
| 4.5       | MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028                                    | 65 |
| FIGURE 19 | PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD                   | 65 |
| 4.6       | MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028                                   | 66 |
| FIGURE 20 | INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028                             | 66 |

|           |  |    |
|-----------|--|----|
| 4.7       | MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028   | 66 |
| FIGURE 21 | DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD  | 66 |
| 4.8       | MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES  | 67 |
| FIGURE 22 | ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD                 | 67 |
| 5         | MARKET OVERVIEW  | 68 |
| 5.1       | INTRODUCTION   | 68 |
| 5.2       | MARKET DYNAMICS  | 68 |
| FIGURE 23 | MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                                 | 68 |
| 5.2.1     | DRIVERS  | 69 |
| 5.2.1.1   | Increasing prevalence of infectious diseases and cancer globally   | 69 |
| TABLE 1   | ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025                                  | 71 |
| TABLE 2   | GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025  | 71 |
| 5.2.1.2   | Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies                   | 71 |
| 5.2.1.3   | Growing awareness regarding early disease diagnosis in developing countries                                      | 73 |
| 5.2.1.4   | Rising technological advancements in molecular diagnostics in recent years                                       | 73 |
| 5.2.1.5   | Increasing use of PoC diagnostic tests in homecare settings and hospitals  | 74 |
| 5.2.2     | RESTRAINTS   | 74 |
| 5.2.2.1   | Unfavorable reimbursement scenario for diagnostic companies  | 74 |
| 5.2.2.2   | High cost of molecular diagnostic instruments  | 74 |
| 5.2.3     | OPPORTUNITIES  | 75 |
| 5.2.3.1   | Growing significance of companion diagnostics in drug development process  | 75 |
| 5.2.3.2   | Increasing growth opportunities for molecular diagnostics companies in emerging economies                        | 75 |
| 5.2.4     | CHALLENGES   | 76 |
| 5.2.4.1   | Changing regulatory landscape for IVD and molecular diagnostics in US and European Union                         | 76 |
| 5.2.4.2   | Operational barriers and shortage of skills across major markets   | 76 |
| 5.2.4.3   | Introduction of alternative technologies for disease detection and diagnosis                                     | 76 |
| 5.3       | PRICING ANALYSIS   | 77 |
| 5.3.1     | AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER   | 77 |
| TABLE 3   | AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS   | 77 |
| 5.4       | PATENT ANALYSIS  | 78 |
| FIGURE 24 | PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)              | 78 |
| 5.4.1     | LIST OF MAJOR PATENTS  | 79 |
| 5.5       | VALUE CHAIN ANALYSIS   | 80 |
| FIGURE 25 | VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES | 81 |
| 5.6       | SUPPLY CHAIN ANALYSIS  | 82 |
| FIGURE 26 | MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS  | 82 |
| 5.7       | ECOSYSTEM/MARKET MAP ANALYSIS  | 83 |
| FIGURE 27 | MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS  | 83 |
| 5.7.1     | MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM  | 84 |
| 5.8       | PORTER'S FIVE FORCES ANALYSIS  | 84 |
| TABLE 4   | MOLECULAR DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS  | 84 |
| 5.8.1     | THREAT FROM NEW ENTRANTS   | 85 |
| 5.8.2     | THREAT FROM SUBSTITUTES  | 85 |
| 5.8.3     | BARGAINING POWER OF BUYERS   | 85 |
| 5.8.4     | BARGAINING POWER OF SUPPLIERS  | 85 |
| 5.8.5     | INTENSITY OF COMPETITIVE RIVALRY   | 85 |

## 5.9 REGULATORY ANALYSIS 86

TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86

TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87

TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87

TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87

### 5.9.1 NORTH AMERICA 87

#### 5.9.1.1 US 87

#### 5.9.1.2 Canada 87

### 5.9.2 EUROPE 88

TABLE 9 EUROPE: CLASSIFICATION OF DEVICES 88

### 5.9.3 ASIA PACIFIC 89

#### 5.9.3.1 China 89

#### 5.9.3.2 Japan 89

TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89

#### 5.9.3.3 India 89

### 5.9.4 LATIN AMERICA 90

#### 5.9.4.1 Brazil 90

#### 5.9.4.2 Mexico 90

### 5.9.5 MIDDLE EAST 90

### 5.9.6 AFRICA 91

## 5.10 TRADE ANALYSIS 91

### 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 91

5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million) 91

5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million) 91

### 5.11 TECHNOLOGY ANALYSIS 91

### 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024 93

TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023-2024 93

### 5.13 PESTLE ANALYSIS 95

### 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 96

#### 5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET 96

### 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 96

#### 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 96

FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS 96

TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%) 97

#### 5.15.2 BUYING CRITERIA 97

FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS 97

TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS 98

### 5.16 CASE STUDY ANALYSIS 98

FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA 98

## 6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 99

### 6.1 INTRODUCTION 100

TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 100

TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022) 100

### 6.2 REAGENTS & KITS 101

#### 6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET 101

TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION) 102

### 6.3 INSTRUMENTS 102

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|          |   |     |
|----------|---|-----|
| 6.3.1    | INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET   | 102 |
| TABLE 17 | KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET  | 103 |
| TABLE 18 | MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)                                      | 103 |
| 6.4      | SERVICES & SOFTWARE   | 104 |
| 6.4.1    | INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH                             | 104 |
| TABLE 19 | MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021-2028 (USD MILLION)                              | 104 |
| 7        | MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE  | 105 |
| 7.1      | INTRODUCTION  | 106 |
| TABLE 20 | MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)   | 106 |
| 7.1.1    | PRIMARY NOTES   | 106 |
| 7.1.1.1  | Key industry insights   | 106 |
| 7.2      | LAB TESTS   | 107 |
| 7.2.1    | ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET                | 107 |
| TABLE 21 | MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021-2028 (USD MILLION)  | 108 |
| 7.3      | POC TESTS   | 108 |
| 7.3.1    | FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH   | 108 |
| TABLE 22 | MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021-2028 (USD MILLION)  | 109 |
| 8        | MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE  | 110 |
| 8.1      | INTRODUCTION  | 111 |
| TABLE 23 | MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)   | 111 |
| 8.2      | BLOOD, SERUM, AND PLASMA  | 111 |
| 8.2.1    | UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET                            | 111 |
| TABLE 24 | MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)                         | 112 |
| 8.3      | URINE   | 112 |
| 8.3.1    | NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH   | 112 |
| TABLE 25 | MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)  | 113 |
| 8.4      | OTHER SAMPLE TYPES  | 113 |
| TABLE 26 | MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)                               | 113 |
| 9        | MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY   | 114 |
| 9.1      | INTRODUCTION  | 115 |
| 9.1.1    | PRIMARY NOTES   | 115 |
| 9.1.1.1  | Key industry insights   | 115 |
| TABLE 27 | MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)  | 116 |
| 9.2      | POLYMERASE CHAIN REACTION   | 116 |
| 9.2.1    | GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET                                   | 116 |
| TABLE 28 | MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION)                        | 117 |
| 9.3      | ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY  | 117 |
| 9.3.1    | COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET          | 117 |
| TABLE 29 | MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION) | 118 |
| 9.4      | DNA SEQUENCING & NEXT-GENERATION SEQUENCING   | 118 |
| 9.4.1    | INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET                                       | 118 |
| TABLE 30 | MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)      | 119 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## 9.5 IN SITU HYBRIDIZATION 120

### 9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET 120

TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION) 120

## 9.6 DNA MICROARRAYS 121

### 9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS 121

TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION) 121

## 9.7 OTHER TECHNOLOGIES 122

TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION) 122

## 10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 123

### 10.1 INTRODUCTION 124

TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 124

### 10.2 INFECTIOUS DISEASE DIAGNOSTICS 124

TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION) 125

TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION) 125

#### 10.2.1 HEPATITIS 126

10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment 126

TABLE 37 HEPATITIS MARKET, BY REGION, 2021-2028 (USD MILLION) 126

TABLE 38 HEPATITIS MARKET, BY REGION, 2021-2028 (MILLION TESTS) 127

#### 10.2.2 HIV 127

10.2.2.1 Increased global prevalence of HIV to propel segment 127

TABLE 39 HIV MARKET, BY REGION, 2021-2028 (USD MILLION) 127

TABLE 40 HIV MARKET, BY REGION, 2021-2028 (MILLION TESTS) 128

#### 10.2.3 CT/NG 128

10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally 128

TABLE 41 CT/NG MARKET, BY REGION, 2021-2028 (USD MILLION) 129

TABLE 42 CT/NG MARKET, BY REGION, 2021-2028 (MILLION TESTS) 129

#### 10.2.4 HAI 129

10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market 129

TABLE 43 HAI MARKET, BY REGION, 2021-2028 (USD MILLION) 130

TABLE 44 HAI MARKET, BY REGION, 2021-2028 (MILLION TESTS) 130

#### 10.2.5 HPV 131

10.2.5.1 Technological advancements for preventing HPV infections to augment market 131

TABLE 45 HPV MARKET, BY REGION, 2021-2028 (USD MILLION) 131

TABLE 46 HPV MARKET, BY REGION, 2021-2028 (MILLION TESTS) 131

#### 10.2.6 TUBERCULOSIS 132

10.2.6.1 Increasing burden of TB globally to propel market 132

TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (USD MILLION) 132

TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (MILLION TESTS) 133

#### 10.2.7 INFLUENZA 133

10.2.7.1 Rising focus on decreasing spread of influenza to propel segment 133

TABLE 49 INFLUENZA MARKET, BY REGION, 2021-2028 (USD MILLION) 134

TABLE 50 INFLUENZA MARKET, BY REGION, 2021-2028 (MILLION TESTS) 134

#### 10.2.8 OTHER INFECTIOUS DISEASES 134

TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION) 135

### 10.3 ONCOLOGY TESTING 135

TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION) 136

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



|           |  |     |
|-----------|--|-----|
| TABLE 53  | MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021-2028 (USD MILLION)              | 137 |
| 10.3.1    | BREAST CANCER  | 137 |
| 10.3.1.1  | Increasing prevalence of breast cancer among females to boost market                               | 137 |
| TABLE 54  | BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040  | 137 |
| TABLE 55  | BREAST CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)   | 138 |
| 10.3.2    | COLORECTAL CANCER  | 138 |
| 10.3.2.1  | Rising focus on development of companion diagnostic assays to fuel market                          | 138 |
| TABLE 56  | COLORECTAL CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)                                       | 138 |
| 10.3.3    | LUNG CANCER  | 139 |
| 10.3.3.1  | Increasing research for lung cancer biomarkers to drive market                                     | 139 |
| TABLE 57  | LUNG CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)   | 139 |
| 10.3.4    | PROSTATE CANCER  | 139 |
| 10.3.4.1  | Advancements in genomic technologies for development of new biomarkers to aid market               | 139 |
| TABLE 58  | PROSTATE CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)   | 140 |
| 10.3.5    | OTHER CANCERS  | 140 |
| TABLE 59  | GLOBAL CANCER INCIDENCE, 2020  | 140 |
| TABLE 60  | OTHER CANCERS MARKET, BY REGION, 2021-2028 (USD MILLION)   | 141 |
| 10.4      | GENETIC TESTING  | 141 |
| 10.4.1    | DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET                     | 141 |
| TABLE 61  | MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021-2028 (USD MILLION)               | 141 |
| 10.5      | OTHER APPLICATIONS   | 142 |
| TABLE 62  | MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)            | 142 |
| 10.6      | COVID-19   | 142 |
| 10.6.1    | DECLINING CASES OF COVID-19 TO HINDER MARKET   | 142 |
| TABLE 63  | MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)                      | 143 |
| 11        | MOLECULAR DIAGNOSTICS MARKET, BY END USER  | 144 |
| 11.1      | INTRODUCTION   | 145 |
| TABLE 64  | MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                 | 145 |
| 11.2      | DIAGNOSTIC LABORATORIES  | 145 |
| 11.2.1    | INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET               | 145 |
| TABLE 65  | MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)       | 146 |
| 11.3      | HOSPITALS & CLINICS  | 146 |
| 11.3.1    | GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT       | 146 |
| TABLE 66  | MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)           | 147 |
| 11.4      | OTHER END USERS  | 147 |
| TABLE 67  | MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)               | 148 |
| 12        | MOLECULAR DIAGNOSTICS MARKET, BY REGION  | 149 |
| 12.1      | INTRODUCTION   | 150 |
| TABLE 68  | MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)                                   | 150 |
| 12.2      | NORTH AMERICA  | 150 |
| FIGURE 31 | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT   | 152 |
| TABLE 69  | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)                   | 152 |
| TABLE 70  | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)         | 153 |
| TABLE 71  | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)               | 153 |
| TABLE 72  | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                | 154 |
| TABLE 73  | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)               | 154 |
| TABLE 74  | NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 |     |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION)155

TABLE 75NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)155

TABLE 76NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)156

12.2.1IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA156

12.2.2US156

12.2.2.1Increasing prevalence of infectious diseases and cancer to drive market156

TABLE 77US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)157

TABLE 78US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)157

TABLE 79US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)158

TABLE 80US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)158

TABLE 81US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)159

TABLE 82US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)159

12.2.3CANADA159

12.2.3.1High availability of funding for genomics research to fuel market159

TABLE 83CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)160

TABLE 84CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)160

TABLE 85CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)161

TABLE 86CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)161

TABLE 87CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)162

TABLE 88CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)162

12.3EUROPE162

TABLE 89EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)163

TABLE 90EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)163

TABLE 91EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)164

TABLE 92EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)164

TABLE 93EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)165

TABLE 94EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)165

TABLE 95EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)166

TABLE 96EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)166

12.3.1IMPACT OF ECONOMIC RECESSION ON EUROPE166

12.3.2GERMANY167

12.3.2.1Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market167

TABLE 97GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)167

TABLE 98GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)168

TABLE 99GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)168

TABLE 100GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)169

TABLE 101GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)169

TABLE 102GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)170

12.3.3UK170

12.3.3.1Growing number of accredited diagnostic laboratories to fuel market170

TABLE 103UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)171

TABLE 104UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)171

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|           |   |     |
|-----------|---|-----|
| TABLE 105 | UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)   | 171 |
| TABLE 106 | UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)             | 172 |
| TABLE 107 | UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                           | 172 |
| TABLE 108 | UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)  | 173 |
| 12.3.4    | FRANCE  | 173 |
| 12.3.4.1  | Rising R&D expenditure and increasing demand for early disease diagnosis to augment market                        | 173 |
| TABLE 109 | FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                               | 173 |
| TABLE 110 | FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                      | 174 |
| TABLE 111 | FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                     | 174 |
| TABLE 112 | FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)         | 175 |
| TABLE 113 | FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                       | 175 |
| TABLE 114 | FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)  | 176 |
| 12.3.5    | ITALY   | 176 |
| 12.3.5.1  | Adoption of advanced diagnostic technologies to support market  | 176 |
| TABLE 115 | ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                                | 177 |
| TABLE 116 | ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                       | 177 |
| TABLE 117 | ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                      | 177 |
| TABLE 118 | ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)          | 178 |
| TABLE 119 | ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                        | 178 |
| TABLE 120 | ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)   | 179 |
| 12.3.6    | SPAIN   | 179 |
| 12.3.6.1  | Growing demand for genetic testing to create major growth opportunities for market players                        | 179 |
| TABLE 121 | SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                                | 180 |
| TABLE 122 | SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                       | 180 |
| TABLE 123 | SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                      | 181 |
| TABLE 124 | SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)          | 181 |
| TABLE 125 | SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                        | 182 |
| TABLE 126 | SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)   | 182 |
| 12.3.7    | RUSSIA  | 182 |
| 12.3.7.1  | Increasing access to quality healthcare and growing incidence of infectious diseases to aid market                | 182 |
| TABLE 127 | RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                               | 183 |
| TABLE 128 | RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                      | 183 |
| TABLE 129 | RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                     | 184 |
| TABLE 130 | RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)         | 184 |
| TABLE 131 | RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                       | 185 |
| TABLE 132 | RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)  | 185 |
| 12.3.8    | REST OF EUROPE  | 185 |
| TABLE 133 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                       | 186 |
| TABLE 134 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                              | 186 |
| TABLE 135 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                             | 187 |
| TABLE 136 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION) | 187 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|           |   |     |
|-----------|---|-----|
| TABLE 137 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)             | 188 |
| TABLE 138 | REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                              | 188 |
| 12.4      | ASIA PACIFIC  | 188 |
| FIGURE 32 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT   | 189 |
| TABLE 139 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)                                 | 190 |
| TABLE 140 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                       | 190 |
| TABLE 141 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)                             | 190 |
| TABLE 142 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                              | 191 |
| TABLE 143 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                             | 191 |
| TABLE 144 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION) | 192 |
| TABLE 145 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)               | 192 |
| TABLE 146 | ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                | 193 |
| 12.4.1    | IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC  | 193 |
| 12.4.2    | CHINA   | 193 |
| 12.4.2.1  | Rapid economic growth and greater public access to modern healthcare to drive market                            | 193 |
| TABLE 147 | CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                              | 194 |
| TABLE 148 | CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                     | 194 |
| TABLE 149 | CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                    | 195 |
| TABLE 150 | CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)        | 195 |
| TABLE 151 | CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                      | 196 |
| TABLE 152 | CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                       | 196 |
| 12.4.3    | JAPAN   | 196 |
| 12.4.3.1  | Universal healthcare reimbursement policy to support market   | 196 |
| TABLE 153 | JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                              | 197 |
| TABLE 154 | JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                     | 197 |
| TABLE 155 | JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                    | 198 |
| TABLE 156 | JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)        | 198 |
| TABLE 157 | JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                      | 199 |
| TABLE 158 | JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                       | 199 |
| 12.4.4    | INDIA   | 199 |
| 12.4.4.1  | Increased private & public investments and large patient population to drive market                             | 199 |
| TABLE 159 | INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                              | 200 |
| TABLE 160 | INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                     | 201 |
| TABLE 161 | INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                    | 201 |
| TABLE 162 | INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)        | 202 |
| TABLE 163 | INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                      | 202 |
| TABLE 164 | INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                       | 203 |
| 12.4.5    | AUSTRALIA   | 203 |
| 12.4.5.1  | High prevalence of infectious diseases to fuel market   | 203 |
| TABLE 165 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                          | 203 |
| TABLE 166 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                 | 204 |
| TABLE 167 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                | 204 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

|           |   |     |
|-----------|---|-----|
| TABLE 168 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)            | 205 |
| TABLE 169 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                          | 205 |
| TABLE 170 | AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)   | 206 |
| 12.4.6    | REST OF ASIA PACIFIC  | 206 |
| TABLE 171 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                       | 207 |
| TABLE 172 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                              | 207 |
| TABLE 173 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                             | 208 |
| TABLE 174 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION) | 208 |
| TABLE 175 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)               | 209 |
| TABLE 176 | REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                | 209 |
| 12.5      | LATIN AMERICA   | 209 |
| TABLE 177 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)  | 210 |
| TABLE 178 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                              | 210 |
| TABLE 179 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)                                    | 210 |
| TABLE 180 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                                     | 211 |
| TABLE 181 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                                    | 211 |
| TABLE 182 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)        | 212 |
| TABLE 183 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                      | 212 |
| TABLE 184 | LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)                                       | 213 |
| 12.5.1    | IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA   | 213 |
| 12.5.2    | BRAZIL  | 213 |
| 12.5.2.1  | Improving healthcare infrastructure and stringent regulations to fuel market  | 213 |
| TABLE 185 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                                     | 214 |
| TABLE 186 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)  | 214 |
| TABLE 187 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)   | 215 |
| TABLE 188 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)               | 215 |
| TABLE 189 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                             | 216 |
| TABLE 190 | BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)  | 216 |
| 12.5.3    | MEXICO  | 216 |
| 12.5.3.1  | Improving accessibility and affordability of healthcare services to aid market  | 216 |
| TABLE 191 | MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                                     | 217 |
| TABLE 192 | MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)  | 217 |
| TABLE 193 | MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)   | 218 |
| TABLE 194 | MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)               | 218 |
| TABLE 195 | MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)                             | 219 |
| TABLE 196 | MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)  | 219 |
| 12.5.4    | REST OF LATIN AMERICA   | 219 |
| TABLE 197 | REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)                      | 220 |
| TABLE 198 | REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)                             | 220 |
| TABLE 199 | REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)                            | 221 |
| TABLE 200 | REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE,                        |     |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

2021-2028 (USD MILLION)221

TABLE 201REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)222

TABLE 202REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)222

## Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028

Market Report | 2023-07-03 | 310 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

| Select license | License                 | Price      |
|----------------|-------------------------|------------|
|                | Single User             | \$4950.00  |
|                | Multi User              | \$6650.00  |
|                | Corporate License       | \$8150.00  |
|                | Enterprise Site License | \$10000.00 |
|                |                         | VAT        |
|                |                         | Total      |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |                      |
|---------------|----------------------|-------------------------------|----------------------|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/> |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/> |
| Job title*    | <input type="text"/> |                               |                      |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address*      | <input type="text"/> | City*                         | <input type="text"/> |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/> |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-20

Signature



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)